Epirus Biopharmaceuticals Inc  

(Public, NASDAQ:EPRS)   Watch this stock  
Find more results for MALLINCKRODT, INC
8.95
0.00 (0.00%)
Mar 31 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 3.78 - 17.40
Open     -
Vol / Avg. 0.00/335,122.00
Mkt cap 201.68M
P/E     -
Div/yield     -
EPS -4.10
Shares 22.53M
Beta 2.31
Inst. own 33%
May 7, 2015
Q1 2015 EPIRUS Biopharmaceuticals Inc Earnings Release (Estimated) Add to calendar
Mar 24, 2015
Q4 2014 EPIRUS Biopharmaceuticals Inc Earnings Call
Mar 23, 2015
Q4 2014 EPIRUS Biopharmaceuticals Inc Earnings Release
Feb 12, 2015
Epirus Biopharmaceuticals Inc at Leerink Global Healthcare Conference
Jan 12, 2015
Epirus Biopharmaceuticals Inc at EBD Biotech Showcase
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -260000.00% -1046100.00%
Operating margin -253900.00% -981375.00%
EBITD margin - -981375.00%
Return on average assets -79.28% -143.84%
Return on average equity -111.54% -
Employees 27 -
CDP Score - -

Address

699 Boylston St Fl 11
BOSTON, MA 02116-2848
United States - Map
+1-617-6004164 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

EPIRUS Biopharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the research, development, manufacturing and commercialization of biosimilar therapeutics. The Company�s pipeline of biosimilar product candidates includes BOW015, a biosimilar version of infliximab;BOW050, a biosimilar version of Humira (adalimumab), and BOW070, a biosimilar version of Actemra (tocilizumab). BOW050 (Adalimumab) and BOW070 (Tocilizumab) are in the preclinical stage of development. The Company�s lead product candidate is BOW015, which is indicated for the treatment of various inflammatory diseases, including rheumatoid arthritis, Crohn's Disease, ankylosing spondylitis, psoriatic arthritis and psoriasis.

Officers and directors

Amit Munshi President, Chief Executive Officer, Director
Age: 46
Bio & Compensation  - Reuters
Thomas Shea Chief Financial Officer
Age: 54
Bio & Compensation  - Reuters
J. Kevin Buchi Director
Bio & Compensation  - Reuters
Mark H. N. Corrigan M.D. Director
Age: 56
Bio & Compensation  - Reuters
Geoffrey M. Duyk M.D., Ph.D. Director
Age: 55
Bio & Compensation  - Reuters
Daotian Fu Director
Bio & Compensation  - Reuters
Julie McHugh Director
Bio & Compensation  - Reuters